This inventor holds 4 USPTO granted patents and 1 published patent application. Top assignees: Glaxo Wellcome Inc., Smithkline Beecham Corporation. Active years: 2000-2003.
Location History:
- Rayston, GB (2001)
- Royston, GB (2002)
- Stevenage, GB (2000 - 2003)
Company Filing History:
Years Active: 2000-2003
Title: Christopher John Wallis: Innovator in Pharmaceutical Chemistry
Introduction
Christopher John Wallis is a notable inventor based in Stevenage, GB. He has made significant contributions to the field of pharmaceutical chemistry, holding a total of 4 patents. His work primarily focuses on processes that enhance the synthesis of important chemical compounds.
Latest Patents
Among his latest patents, Wallis has developed a process for the synthesis of chloropurine intermediates. This invention relates to a method for preparing a carbocyclic purine nucleoside analogue, which involves hydrolyzing a specific compound in the presence of an acid and subsequently condensing the product with another compound. Additionally, he has patented a process for preparing enantiomerically enriched N-derivatized lactams using enzymatic methods. These innovations demonstrate his expertise in creating valuable pharmaceutical intermediates.
Career Highlights
Throughout his career, Wallis has worked with prominent companies in the pharmaceutical industry, including SmithKline Beecham Corporation and Glaxo Wellcome Inc. His experience in these organizations has allowed him to contribute to various projects that advance drug development and synthesis techniques.
Collaborations
Wallis has collaborated with several professionals in his field, including Martin Francis Jones and Michael John Dawson. These partnerships have likely enriched his research and development efforts, leading to innovative solutions in pharmaceutical chemistry.
Conclusion
Christopher John Wallis is a distinguished inventor whose work in pharmaceutical chemistry has led to significant advancements in the synthesis of important chemical compounds. His contributions continue to impact the industry positively.